Physician profile
Margo L Thomas
NPI 1114138658
$4,550.24
in general payments reported to CMS, 2019-2025
23 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,190 · 2020: $54.38 · 2021: $643 · 2022: $287 · 2024: $112 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $666.84 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $642.71 | 2019-2024 | Farxiga |
| Lilly USA, LLC | $418.81 | 2019-2025 | Mounjaro |
| Janssen Pharmaceuticals, INC | $337.47 | 2019 | |
| Glaxosmithkline, LLC. | $283.74 | 2019-2020 | |
| Pfizer INC. | $270.81 | 2019 | |
| Esperion Therapeutics, INC. | $250.00 | 2021 | |
| Allergan, INC. | $239.37 | 2019-2020 | |
| Amgen INC. | $192.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $181.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $171.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.02 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.52 | 2019 | |
| Amarin Pharma, INC. | $131.24 | 2019-2022 | |
| Mylan Specialty L.P. | $118.47 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $116.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.59 | 2019 | |
| Shire North American Group INC | $61.41 | 2019 | |
| Abbvie INC. | $29.68 | 2021 | |
| Astellas Pharma US INC | $27.12 | 2019-2025 | Veozah |
| Ironwood Pharmaceuticals, INC | $13.27 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.71 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margo Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.